FDG-PET/CT vs. Non-FDG Tracers in Less Explored Domains, An Issue of PET Clinics
In this issue, guest editors bring their considerable expertise to this important topic.
Key Features
Provides in-depth reviews on the latest updates in the field, providing actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create these timely topic-based reviews.
| ISBN | 9780323897181 |
|---|---|
| Product Format | Book |
| Publication Date | 2022 |
| Author Information | Edited by Sandip Basu, DRM, DNB, MNAMS, Professor, Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe, Mumbai, Maharashtra, India; Rakesh Kumar, Director, CSIR-National Environmental Engineering Research Institute (CSIR-NEERI), Nehru Marg, Nagpur, Maharashtra, India and Abass Alavi, MD, Professor, Division of Nuclear Medicine, Department of Radiology, Hospital of the, University of Pennsylvania, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania |
| Table of Content | Facts and Fictions About [18F]FDG versus Other Tracers in Managing Patients with Brain Tumors: It Is Time to Rectify the Ongoing Misconceptions An Appraisal and Update of Fluorodeoxyglucose and Non-Fluorodeoxyglucose-PET Tracers in Thyroid and Non-Thyroid Endocrine Neoplasms 18F-Fluorodeoxyglucose-PET-Computerized Tomography and non-Fluorodeoxyglucose PET-Computerized Tomography in Hepatobiliary and Pancreatic Malignancies Molecular Imaging Assessment of Androgen Deprivation Therapy in Prostate Cancer Molecular Imaging Assessment of Hormonally Sensitive Breast Cancer: An Appraisal of 2- [18F]-Fluoro-2-Deoxy-Glucose and Newer Non-2-[18F]-Fluoro-2-Deoxy-Glucose PET Tracers 18F-FDG Versus Non-FDG PET Tracers in Multiple Myeloma Role of Molecular Imaging with PET/MR Imaging in the Diagnosis and Management of Brain Tumors Fibroblast Activation Protein Inhibitor Theranostics PET-CTBased Quantitative Parameters for Assessment of Treatment Response and Disease Activity in Cancer and Noncancerous Disorders Positron Emission Tomography-Based Assessment of Cognitive Impairment and Dementias, Critical Role of Fluorodeoxyglucose in such Settings Nonmalignant Thoracic Disorders: An Appraisal of Fluorodeoxyglucose and Non>fluorodeoxyglucose PET/Computed Tomography Applications Fluorodeoxyglucose PET/Computed Tomography in Evaluation of Prosthetic Joints and Diabetic Foot: A Comparative Perspective with Other Functional Imaging Modalities Utility of PET/Computed Tomography in Infection and Inflammation Imaging Role of Fluorodeoxyglucose-PET in Interventional Radiology |
| Publication Date | 21-06-2022 |
| Pages | 240 |
| Stock Status | In Stock |
| deltacomm1code | Books |
Write Your Own Review
